From Recognition to Resolution: A Practical Framework for Diagnosing, Treating, and Managing MASH in the Liver/GI Specialty Setting

Pre-registration for:
From Recognition to Resolution: A Practical Framework for Diagnosing, Treating, and Managing MASH in the Liver/GI Specialty Setting

Thursday November 5, 2026

Colorado Convention Center
Four Seasons Ballroom 1
700 14th Street
Denver, Colorado

Register using the form provided below. Click HERE for additional meeting details.
 
Register using the form provided below. Click HERE for additional meeting details.
+ Add a Registration
Security Check *
* Required fields.
Symposium Poster

Program Overview:

Metabolic dysfunction-associated steatohepatitis (MASH) is the progressive, inflammatory form of metabolic dysfunction-associated steatotic liver disease (MASLD) and one of the most rapidly growing causes of end-stage liver disease in the United States. An estimated 14.9 million Americans had MASH in 2020; that figure is projected to reach 23.2 million by 2050. Despite this burden, real-world clinical records capture MASH prevalence at only 0.15% of adults, indicating the vast majority of patients remain unidentified and untreated. The MASH therapeutic landscape has transformed substantially with two FDA approvals in 18 months: resmetirom and semaglutide 2.4 mg/week, both indicated for non-cirrhotic MASH with significant fibrosis. Agent selection requires an understanding of their distinct mechanisms, metabolic effects, comorbidity considerations, monitoring requirements and tolerability differences. Additionally, the non-invasive testing (NIT) frameworks that determine which patients qualify for treatment have been substantially updated by AASLD’s 2025 practice guidelines on blood-based and imaging-based assessment — replacing earlier guidance and requiring integration into clinical workflow. For patients with compensated MASH cirrhosis the fibroblast growth factor 21 (FGF21) analog class represents the most clinically advanced area of investigational research, with ongoing Phase 3 programs in both pre-cirrhotic MASH and compensated cirrhosis. This program is specifically designed for the liver/GI specialty audience: hepatologists, gastroenterologists, and advanced practice providers who manage patients with MASH and are positioned to implement the updated NIT framework, initiate approved pharmacotherapy, and counsel patients on emerging options.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Apply the AASLD-endorsed stepwise non-invasive testing framework — including FIB-4, VCTE/ELF, and MRE — to identify patients with MASH and significant fibrosis (F2–F3) who are candidates for pharmacotherapy, and describe the role of liver biopsy in cases of diagnostic uncertainty
  • Compare the mechanism of action, Phase 3 clinical evidence, patient selection criteria, and monitoring requirements for resmetirom and semaglutide 2.4 mg/week in patients with non-cirrhotic MASH and F2–F3 fibrosis, and apply this comparison to individualized treatment decisions based on patient comorbidity profile
  • Characterize the FGF21 analog class — including efruxifermin and pegozafermin — by mechanism of action, Phase 2 and Phase 3 evidence to date, and current regulatory status, and describe the evidence supporting the investigational role of FGF21 analogs in patients with pre-cirrhotic MASH and compensated cirrhosis due to MASH
  • Formulate an evidence-based management plan for patients with compensated MASH cirrhosis, including surveillance priorities, appropriate use of approved therapies for comorbid conditions, and accurate patient communication regarding investigational treatment options

Target Audience:

This program is intended for cardiovascular clinicians and other healthcare professionals who manage patients with T2D and ASCVD risk.

Accreditation and Credit Designation Statements

Voxmedia, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Voxmedia, LLC designates this live activity for a maximum of 1.5 AMA PRA Category Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 CreditsTM through its reciprocity agreements. The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 CreditsTM from organizations accredited by the ACCME.

Educational Grant:

Voxmedia International gratefully acknowledges the educational grant from Novo Nordisk Inc.

Disclosure Information

Voxmedia strives to ensure fair-balance, independence, objectivity, and scientific rigor in all directly or jointly sponsored educational activities. All prospective faculty are required to disclose to Voxmedia all financial relationships for the preceding 24 months (1) with any commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients AND (2) with any commercial supporters prior to participating in the planning of an activity or developing content. Only after Voxmedia mitigates all financial relationships may faculty receive approval to participate, and are expected to contribute evidence-based material. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta- analysis. All information submitted will be peer-reviewed. The intent of this disclosure is not to prevent faculty from participating, but rather to provide learners with information on which they can make their own judgment of commercial bias. Voxmedia will disclose to learners that all relevant financial relationships have been mitigated in either written materials, visually and/or verbally. It remains for the audience to determine whether the speaker’s interests or relationships may influence the presentation. Speakers must make a meaningful disclosure to the audience of their discussions of any unlabeled or investigational use(s) of drugs or devices.

Americans with Disabilities Act:

Voxmedia fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant of this activity is in need of accommodation, please call and/or submit in writing to: Voxmedia, 1 Bethany Rd. Bldg 3, Suite 48, Hazlet, NJ 07730. Phone: 973-467-0500.